Cytos to fold after PhIIb asthma vaccine failure
This article was originally published in Scrip
The failure of Cytos Biotechnology's last remaining hope, the asthma vaccine candidate CYT003, in a Phase IIb study has sounded the death knell for the Swiss company. The company is to explore winding down and liquidating, or a possible bankruptcy, after deciding that the prospects of raising new funding that would enable it to continue as a going concern are "remote".
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.